The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial.

ABSTRACT:

Background

The Raynaud's condition score (RCS) is a validated outcome measure for Raynaud's phenomenon (RP).

Objective

To assess the minimally important difference (MID) and patient acceptable symptom state (PASS) for RCS in patients with RP.

Subjects

and methods Patients with active RP (n=162) (mean RCS >25 (0-100 visual analogue scale) participated in a placebo-controlled, crossover randomised clinical trial (RCT). Data from the two treatment groups were combined for this analysis. Retrospective and prospective anchors were administered during the RCT. MID groups were defined as the group who reported being somewhat better (anchor #1) and a one-step change from "unbearable" to "very severe", etc (anchor #2). Patients were considered to have achieved PASS if they rat

SUBMITTER: Khanna PP 

PROVIDER: S-EPMC2837770 | biostudies-literature | 2010 Mar

REPOSITORIES: biostudies-literature